Trials / Completed
CompletedNCT00478855
Tazocin Intervention Study
Association of Antibiotic Utilization Measures and Control of ESBLs Producing Bacteria
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 500 (planned)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
1. To determine the value of using piperacillin/tazobactam in reducing the cases of extended spectrum beta lactamases (ESBL) producing E. coli or K. pneumoniae colonization and infection. 2. To determine the acquisition rate of ESBL producing E. coli or K. pneumoniae, both pre-and post-intervention in the selected medical centers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tazocin (Piperacillin/Tazobactem) |
Timeline
- Start date
- 2006-09-01
- Completion
- 2007-06-01
- First posted
- 2007-05-25
- Last updated
- 2007-12-10
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT00478855. Inclusion in this directory is not an endorsement.